WC
KPTI icon

Woodstock Corp’s Karyopharm Therapeutics KPTI Stock Holding History

Woodstock Corp’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,599
Closed -$1.19M – 166
2015
Q1 		$1.19M Buy
2,599
+1,432
+123% +$617K 0.22% 92
2014
Q4 		$655K Buy
+1,167
New +$663K 0.12% 110

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Woodstock Corp's KPTI Position: Q2 2015 in Review

Woodstock Corp sold out of Karyopharm Therapeutics (KPTI) in Q2 2015, closing a stake of 2,599 shares — an estimated $1.19M sold.

Woodstock Corp first reported a position in KPTI in Q4 2014 and held it in 2 quarters. The position peaked at $1.19M in Q1 2015. 89 funds tracked by Wall St. Rank hold KPTI as of Q2 2015.

  • Woodstock Corp reported no remaining Karyopharm Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Woodstock Corp sold 2,599 Karyopharm Therapeutics shares in Q2 2015, an estimated $1.19M.
  • Woodstock Corp first reported a position in Karyopharm Therapeutics in Q4 2014 and held it in 2 quarters.
  • Woodstock Corp's Karyopharm Therapeutics position peaked at $1.19M in Q1 2015.
  • 89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2015.

Based on Woodstock Corp's 13F filing for Q2 2015, filed 7 Jul 2015.